TEVIMBRA

( ARTG ) Oesophageal squamous cell carcinoma (OSCC),TEVIMBRA in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma with a PD-L1 expression equal to or greater than 1%.,TEVIMBRA as monotherapy is indicated for the treatment of adult patients with unresectable, recurrent, locally advanced or metastatic oesophageal squamous cell carcinoma after prior chemotherapy.,Non-small cell lung cancer (NSCLC),TEVIMBRA in combination with pemetrexed and platinum containing chemothe‍‍‍‍‍‍​​​‍​​​​​​rapy is indicated for the first-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), with PD-L1 expression equal to or greater than 50% but no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,TEVIMBRA in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of patients with locally advanced or metastatic squamous NSCLC.,TEVIMBRA as monotherapy is indicated for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy.,Gastric/Gastro-oesophageal Junction (G/GOJ) Adenocarcinoma,TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (G/GOJ) adenocarcinoma with a PD-L1 expression equal to or greater than 1%.,Nasopharyngeal carcinoma (NPC),TEVIMBRA in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).